American Renal Associates Holdings, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net patient service operating revenues of $194,378,000 compared to $199,114,000 a year ago. Operating income was $33,931,000 compared to $25,200,000 a year ago. Income before income taxes was $28,467,000 compared to $14,394,000 a year ago. Net income was $19,718,000 compared to $16,560,000 a year ago. Net income attributable to the company was $231,000 or $0.05 per basic and diluted share compared to loss of $7,119,000 or $0.02 per diluted share a year ago. Cash provided by operating activities was $31,175,000 compared to $30,308,000 a year ago. Purchases of property and equipment were $11,293,000 compared to $14,773,000 a year ago. Adjusted EBITDA (including noncontrolling interests) was $48,051,000 compared to $55,880,000 a year ago. Adjusted EBITDA-NCI was $28,564,000 compared to $32,201,000 a year ago. Adjusted net income attributable to the company was $5,982,000 or $0.18 per share. Adjusted cash provided by operating activities was $31,175,000 compared to $30,308,000 a year ago. Total capital expenditure was $11,293,000 compared to $14,773,000 a year ago. As at December 31, 2017, the company's net debt was $459.5 million.

For the year, the company reported net patient service operating revenues of $745,106,000 compared to $749,767,000 a year ago. Operating income was $106,458,000 compared to $126,807,000 a year ago. Income before income taxes was $83,877,000 compared to $87,452,000 a year ago. Net income was $75,683,000 compared to $88,205,000 a year ago. Net income attributable to the company was $4,857,000 or $0.24 per basic and diluted loss per share compared to loss of $385,000 or $0.28 per diluted share a year ago. Cash provided by operating activities was $128,547,000 compared to $172,211,000 a year ago. Purchases of property and equipment were $36,073,000 compared to $61,432,000 a year ago. Adjusted EBITDA (including noncontrolling interests) was $176,357,000 compared to $212,172,000 a year ago. Adjusted EBITDA-NCI was $105,531,000 compared to $123,582,000 a year ago. Adjusted net income attributable to the company was $2,550,000 or $0.61 per share. Adjusted cash provided by operating activities was $129,264,000 compared to $174,450,000 a year ago. Total capital expenditures were $36,073,000 compared to $61,432,000 a year ago.

The company provided earnings guidance for the full year of 2018. The company expects 2018 adjusted EBITDA-NCI to be in a range of $110 million and $116 million.